Comparison of Binding of N3‵→ P5‵ Phosphoramidate and Phosphorothioate Oligonucleotides to Cell Surface Proteins of Cultured Cells
- 1 February 1999
- journal article
- research article
- Published by Mary Ann Liebert Inc in Antisense and Nucleic Acid Drug Development
- Vol. 9 (1) , 61-69
- https://doi.org/10.1089/oli.1.1999.9.61
Abstract
The binding of uniformly modified N3‵→P5‵ phosphoramidate and stereorandom and stereopure phosphorothioate oligonucleotides (ODN) to cell surface proteins was studied, using both a fibroblast and an epithelial cell line, to assess the effect of different analog backbone types and base composition on cell surface protein binding. Marked differences were observed, both quantitative and qualitative, in the proteins to which individual ODN bound. One phosphoramidate, antisense to the insulin-like growth factor-1 (IGF-1) receptor (IGF-1R), bound to different proteins than did either a 6-base mismatch phosphoramidate IGF-1R sequence or a sense N-ras sequence. The latter bound poorly to the fibroblast line and predominantly to a 46 kDa protein in the epithelial line, as did many of the other ODN. This binding was not so marked as that of the isosequential end-capped phosphodiester N-ras sequence, which bound to this protein in both cell lines. Stereopure and stereorandom phosphorothioates containing a G-quartet (shown in other studies to form high-order tetrad structures), antisense to c-myc, exhibited considerable nonspecific binding to many proteins, as did the isosequential phosphoramidate. In particular, this ODN sequence gave notable binding to high molecular weight proteins. In general, binding of the c-myc ODN to proteins of 28-30, 46, 67, and 70-90 kDa was found in this study.Keywords
This publication has 35 references indexed in Scilit:
- Fluorescence Microscopic Comparison of the Binding of Phosphodiester and Phosphorothioate (Antisense) Oligodeoxyribonucleotides to Subcellular Structures, Including Intermediate Filaments, the Endoplasmic Reticulum, and the Nuclear InteriorAntisense and Nucleic Acid Drug Development, 1997
- Controversies in the Cellular Pharmacology of OligodeoxynucleotidesAntisense and Nucleic Acid Drug Development, 1997
- Identification of an Oligodeoxynucleotide Sequence Motif That Specifically Inhibits Phosphorylation by Protein Tyrosine KinasesAntisense and Nucleic Acid Drug Development, 1997
- Developing antisense oligonucleotides from the laboratory to clinical trialsDrug Discovery Today, 1996
- Efficient Inhibition of Transcription Elongationin vitroby Oligonucleotide Phosphoramidates Targeted to Proviral HIV DNAJournal of Molecular Biology, 1996
- The Influence of Polarized Epithelial (Caco-2) Cell Differentiation on the Cellular Binding of Phosphodiester and Phosphorothioate OligonucleotidesAntisense and Nucleic Acid Drug Development, 1996
- Diastereomers of Nucleoside 3'-O-(2-Thio-1,3,2-oxathia(selena)phospholanes): Building Blocks for Stereocontrolled Synthesis of Oligo(nucleoside phosphorothioate)sJournal of the American Chemical Society, 1995
- Phosphorothioate oligonucleotides bind in a non sequence‐specific manner to the nucleolar protein C23/nucleolinFEBS Letters, 1995
- Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapyKidney International, 1995
- Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular MatrixPublished by Elsevier ,1995